drugset / Trial / NCT06810284

Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy

NCT06810284

NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to assess pharmacokinetics features of IV sildenafil in neonates with hypoxic-ischemic encephalopathy and treated by controlled hypothermia. This phase 2 study will prepare a large phase 3 randomized controlled trial to demonstrate the superiority of a combinatory therapy associating IV sildenafil and controlled hypothermia compared to Placebo and controlled hypothermia, on survival without brain lesions on MRI at discharge, in neonates born after 36 weeks of gestation.

Timeline

Start
2026-10
Primary completion
2027-06
Completion
2029-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sildenafil Unknown 1.6 mg/kg Intravenous